A single-arm, open label, multi-center phase I/II trial to assess the safety and efficacy of BIBF 1120 added to low-dose cytarabine in elderly patients with AML unfit for an intensive induction therapy (BIBF 1120)
Basic data for this project
Type of project: Own resources project
Duration at the University of Münster: 01/01/2010 - 01/12/2020